Peer-reviewed journal article highlights unique oral delivery platform's ability to enhance pharmacokinetic and therapeutic benefit for challenging drugs JERUSALEM , July 1, 2019 /PRNewswire/ --   Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announced that a review

Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients JERUSALEM , June 25, 2019 /PRNewswire/ ---  Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announces that results from an earlier Phase 2 clinical

JERUSALEM , June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) were highlighted yesterday in a

JERUSALEM , May 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in June.  Jefferies Global Healthcare Conference Date: June 4-7, 2019 Company

Strengthens Protection for Accordion Pill Platform JERUSALEM , May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY DEVICE FOR ORAL INTAKE OF

NEW YORK , May 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces it has entered into an agreement with Merck, known as MSD outside the United States and Canada , to explore using the Accordion Pill ® (AP) platform for an undisclosed development

JERUSALEM , May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three months ended March 31, 2019 and provides a corporate update.  Highlights of the first quarter 2019 and recent weeks include: Announced that the last

JERUSALEM , May 2, 2019 /PRNewswire/  -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) was accepted for presentation in

Company on track to report top-line data in July/August time frame JERUSALEM , April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the last patient has completed their final visit in the Company's pivotal Phase 3 trial (the ACCORDANCE

JERUSALEM , April 1, 2019 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference . HC Wainwright Global Life Sciences Conference Date: April 7-9, 2019